In a report released today, Seamus Fernandez from Guggenheim reiterated a Buy rating on MBX Biosciences, Inc., with a price target of $84.00. The company’s shares closed last Friday at $16.69.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Fernandez is a 5-star analyst with an average return of 22.2% and a 63.48% success rate. Fernandez covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Cidara Therapeutics, and Rhythm Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MBX Biosciences, Inc. with a $52.50 average price target, implying a 214.56% upside from current levels. In a report released on September 23, Mizuho Securities also reiterated a Buy rating on the stock with a $56.00 price target.
MBX market cap is currently $746.3M and has a P/E ratio of -7.24.
Read More on MBX:
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
